MwanzoALTME • EPA
add
TME Pharma NV
Bei iliyotangulia
€ 0.057
Bei za siku
€ 0.054 - € 0.065
Bei za mwaka
€ 0.049 - € 0.15
Thamani ya kampuni katika soko
6.01M EUR
Wastani wa hisa zilizouzwa
elfu 359.72
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 13.50 | — |
Matumizi ya uendeshaji wa biashara | elfu 982.00 | -28.24% |
Mapato halisi | -1.05M | 35.28% |
Kiwango cha faida halisi | elfu -7.79 | — |
Mapato kwa kila hisa | — | — |
EBITDA | elfu -965.00 | 27.74% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.06M | -23.79% |
Jumla ya mali | 2.29M | -22.06% |
Jumla ya dhima | 2.86M | 108.22% |
Jumla ya hisa | elfu -570.00 | — |
hisa zilizosalia | 94.09M | — |
Uwiano wa bei na thamani | -5.65 | — |
Faida inayotokana na mali | -105.59% | — |
Faida inayotokana mtaji | -210.54% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -1.05M | 35.28% |
Pesa kutokana na shughuli | -1.43M | -4.57% |
Pesa kutokana na uwekezaji | elfu 4.00 | 200.00% |
Pesa kutokana na ufadhili | elfu 836.00 | -47.78% |
Mabadiliko halisi ya pesa taslimu | elfu -590.00 | -357.64% |
Mtiririko huru wa pesa | elfu -555.00 | 23.25% |
Kuhusu
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1997
Tovuti
Wafanyakazi
12
